Form 4: Neurocrine Biosciences Director Kevin Gorman Exercises Options and Sells Shares

Director Kevin Gorman exercised stock options and sold shares of Neurocrine Biosciences (NBIX) on January 27, 2025, according to a Form 4 filing with the SEC.

Summary

• Kevin Gorman, a director of Neurocrine Biosciences, exercised non-qualified stock options to acquire 146,105 shares of common stock at a price of $32.99 per share on January 27, 2025.
• Simultaneously, Gorman sold 146,105 shares of common stock at a weighted average price of $149.4576 per share, with individual sales prices ranging from $147.20 to $151.49.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 14, 2024.
• Following these transactions, Gorman directly owns 514,596 shares and indirectly owns 514,596 shares through the Gorman and Blais Family Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. A pre-planned sale like this one, under a 10b5-1 plan, is generally viewed as less indicative of management sentiment than discretionary trades.

Comparison to Industry Standards

• It's common for executives at publicly traded biotech companies like Neurocrine Biosciences to receive stock options as part of their compensation packages.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading when selling shares.
• Comparing Gorman's transactions to those of other executives at similar-sized biotech firms (e.g., BioMarin, Vertex) would provide a better understanding of whether the scale of these transactions is typical.

Key Dates